Hypertension in HIV-Infected Adults
Novel Pathophysiologic Mechanisms

Sasha A. Fahme, Gerald S. Bloomfield, Robert Peck

Globally, 37 million people are living with the HIV virus.1 Since the year 2000, the number of individuals with access to antiretroviral therapy (ART) has significantly increased from 700 000 to >16 million.1,2 Widespread ART use has halved the HIV-related mortality rate, from an estimated 2 million deaths in 2005 to 1 million in 2016.1,2 During the same time period though, cardiovascular disease mortality rates more than doubled in people living with HIV.3

Hypertension—the leading risk factor for mortality worldwide—is a growing problem in HIV-infected adults.4–11 HIV-infected adults on ART have a higher prevalence of hypertension when compared with HIV-uninfected individuals.4,6,12–15 A recent meta-analysis of data from around the globe demonstrated that 35% of all HIV-infected adults on ART have hypertension, compared with an estimated 30% of HIV-uninfected adults.6 Among ART-experienced individuals >50 years, >50% have hypertension.6

In addition, HIV-infected adults with hypertension have a higher risk of cardiovascular events and all-cause mortality than HIV-uninfected adults with hypertension or HIV-infected adults with normal blood pressure.8,13,16–18 A prospective cohort study of >80 000 HIV-infected and uninfected American veterans followed during a median 6-year period, for example, found that HIV-infected adults with hypertension had a 2-fold higher risk of incident acute myocardial infarction as compared with HIV-uninfected adults with hypertension.17

Although the epidemiological problem of hypertension in HIV-infected adults is well defined,8,7,9 fewer studies have evaluated the pathophysiologic mechanisms leading to hypertension in people living with HIV. Traditional cardiovascular risk factors explain some, but not all, of the increased hypertension risk among HIV-infected adults.14,19,20 Several virologic and treatment-related factors have been implicated in the pathophysiology of hypertension in HIV infection, among them chronic inflammation, immune reconstitution, and lipodystrophy, all of which uniquely influence common downstream pathways such as the sympathetic and renin–angiotensin–aldosterone systems (RAAS).21–25

Therefore, in this review, we explore the mechanisms of hypertension in HIV infection. Understanding the mechanisms of hypertension in HIV-infected adults is important for 2 reasons. First, increased knowledge of the mechanisms of hypertension in HIV-infected adults will be critical to public health efforts to prevent hypertension, cardiovascular disease, and premature mortality in HIV-infected adults. Second, the study of HIV-specific pathophysiology of hypertension may reveal important immunologic and inflammatory mechanisms of hypertension in the general population. Our review is not intended to be a comprehensive analysis of the numerous mechanisms of hypertension. Instead, we have focused on those mechanisms which might be particularly important in HIV-infected adults. An enhanced understanding of these processes may thereby aid in the development of new preventative and therapeutic interventions for hypertension in HIV-infected adults and for the general population.

Mechanisms

Table 1 lists the published, in vivo human studies describing possible mechanisms for hypertension in HIV-infected adults. Table 2 describes the findings for each of these studies. Figure provides a central, schematic representation of the mechanisms of hypertension in HIV infection. The sections below describe each mechanism individually, including data from the studies in these tables and data from other human and animal studies. We searched PubMed (up to December 2017) and EMBASE (up to December 2017) for relevant articles using the terms HIV and hypertension in combination with the following medical subjecting heading terms and keywords: pathophysiology, blood pressure, kidney/renal injury, kidney/renal dysfunction, endothelial cell, cytokine, lipodystrophy, sympathetic activity, CD4 count, ART, antiretroviral, and weight gain. We included any paper that included previously unreported data regarding mechanisms for the relationship between HIV and hypertension, the metabolic syndrome, or cardiovascular disease. Human, animal, and ex vivo studies were included. We also reviewed bibliographies of included articles to identify additional studies that were not included in the original search.

Microbial Translocation

Microbial gut translocation has been implicated in the pathophysiology of hypertension in HIV-infected adults.21,44 HIV preferentially infects CD (cluster of differentiation) 4 T cells in gut-associated lymphoid defenses and passage of microbes into the systemic circulation.23,44–46 Lipopolysaccharide and soluble CD14 (sCD14), both markers of microbial gut translocation,
have been shown to be associated with hypertension in the context of HIV infection. In a nested, case–control study of HIV-infected adults, new-onset hypertension was associated with higher baseline levels of lipopolysaccharide \((P<0.001)\) and sCD14 \((P=0.024)\). Plasma concentrations of lipopolysaccharide and sCD14 were strongly correlated \((\text{Spearman } \rho=0.62; P=0.01)\) among hypertensive HIV-infected but not normotensive HIV-infected or uninfected controls, implying that a common process, such as microbial translocation, is uniquely associated with these biomarkers in the context of hypertension. Similarly, a case–control study of 458 virologically suppressed HIV-infected adults found elevations in sCD14 preceded and predicted incident hypertension \((\text{odds ratio } [\text{OR}], 1.9; 95\% \text{ confidence interval } [\text{CI}], 1.3–2.6; P<0.001)\).

Lipopolysaccharide is increased in the plasma of HIV-infected participants both before and after initiation of ART. Lipopolysaccharide elevation may cause hypertension in HIV-infected adults through several different pathways. In the general population, lipopolysaccharide has been associated with both arterial stiffness and endothelial cell apoptosis. Furthermore, centrally administered lipopolysaccharide has been shown to promote an inflammatory cascade that ultimately produces prostaglandin E2 and activates the sympathetic nervous system in wild-type mice. Lipopolysaccharide has also been associated with activation of the RAAS. In wild-type mice, lipopolysaccharide has been shown to promote angiotensin II activity by acting on adhesion leukocytes of the endothelium. Lipopolysaccharide also activates RAAS through the peripheral increase of endothelial angiotensin receptors. These receptors were found to trigger an NADPH (nicotinamide adenine dinucleotide phosphate)-mediated cascade that produces reactive oxygen species (ROS) and induces endothelial dysfunction and hypertension. These findings were corroborated by Zhang et al, who studied the effects of lipopolysaccharide in wild-type mice. Cerebroventricular administration of lipopolysaccharide led to increased expression of central angiotensin II receptors, precipitating NADPH-mediated ROS production and activation of the sympathetic nervous system.

### Table 1. Published Human Studies of Novel Mechanisms for Hypertension in HIV-Infected Adults

<table>
<thead>
<tr>
<th>Year</th>
<th>First Author</th>
<th>Journal</th>
<th>Study Design</th>
<th>Country</th>
<th>Sample Size</th>
<th>HIV Infected</th>
<th>HIV Uninfected</th>
<th>ART, %</th>
</tr>
</thead>
<tbody>
<tr>
<td>2005</td>
<td>Thiébaut</td>
<td>Antivir</td>
<td>Prospective cohort</td>
<td>21 countries (Europe, the United States, and Australia)</td>
<td>17 179</td>
<td>0</td>
<td>84</td>
<td></td>
</tr>
<tr>
<td>2006</td>
<td>Crane</td>
<td>AIDS</td>
<td>Prospective cohort</td>
<td>The United States</td>
<td>444</td>
<td>0</td>
<td>100</td>
<td></td>
</tr>
<tr>
<td>2006</td>
<td>Palacios</td>
<td>HIV Med</td>
<td>Prospective cohort</td>
<td>Spain</td>
<td>95</td>
<td>0</td>
<td>100</td>
<td></td>
</tr>
<tr>
<td>2008</td>
<td>Baekken</td>
<td>Nephrol Dial Transplant</td>
<td>Cross-sectional</td>
<td>Norway</td>
<td>495</td>
<td>2091</td>
<td>72</td>
<td></td>
</tr>
<tr>
<td>2008</td>
<td>Baekken</td>
<td>J Hypertens</td>
<td>Prospective cohort</td>
<td>Norway</td>
<td>542</td>
<td>24 968</td>
<td>71</td>
<td></td>
</tr>
<tr>
<td>2009</td>
<td>Crane</td>
<td>HIV Med</td>
<td>Cross-sectional</td>
<td>The United States</td>
<td>347</td>
<td>0</td>
<td>69</td>
<td></td>
</tr>
<tr>
<td>2012</td>
<td>Freitas</td>
<td>J Clin Hypertens (Greenwich)</td>
<td>Cross-sectional</td>
<td>Portugal</td>
<td>368</td>
<td>0</td>
<td>100</td>
<td></td>
</tr>
<tr>
<td>2013</td>
<td>Glyn</td>
<td>J Hum Hypertens</td>
<td>Cross-sectional</td>
<td>South Africa</td>
<td>53</td>
<td>129</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>2013</td>
<td>Hadigan</td>
<td>Am J Nephrol</td>
<td>Prospective cohort</td>
<td>The United States</td>
<td>182</td>
<td>0</td>
<td>100</td>
<td></td>
</tr>
<tr>
<td>2013</td>
<td>Manner</td>
<td>HIV Med</td>
<td>Prospective cohort</td>
<td>Norway</td>
<td>42</td>
<td>0</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>2013</td>
<td>Manner</td>
<td>J Clin Hypertens (Greenwich)</td>
<td>Prospective cohort</td>
<td>Norway</td>
<td>434</td>
<td>0</td>
<td>57</td>
<td></td>
</tr>
<tr>
<td>2014</td>
<td>Morimoto</td>
<td>Nutrition</td>
<td>Cross-sectional</td>
<td>Brazil</td>
<td>285</td>
<td>0</td>
<td>79</td>
<td></td>
</tr>
<tr>
<td>2014</td>
<td>Peck</td>
<td>BMC Med</td>
<td>Cross-sectional</td>
<td>Tanzania</td>
<td>301</td>
<td>153</td>
<td>50</td>
<td></td>
</tr>
<tr>
<td>2014</td>
<td>Tenorio</td>
<td>J Infect Dis</td>
<td>Case–control</td>
<td>The United States</td>
<td>458</td>
<td>0</td>
<td>100</td>
<td></td>
</tr>
<tr>
<td>2015</td>
<td>Roxy</td>
<td>AIDS Res Hum Retroviruses</td>
<td>Clinical trial</td>
<td>Netherlands</td>
<td>50</td>
<td>0</td>
<td>100</td>
<td></td>
</tr>
<tr>
<td>2015</td>
<td>Wensink</td>
<td>PLoS One</td>
<td>Cross-sectional</td>
<td>South Africa</td>
<td>903</td>
<td>0</td>
<td>87</td>
<td></td>
</tr>
<tr>
<td>2016</td>
<td>Castley</td>
<td>PLoS One</td>
<td>Cross-sectional</td>
<td>Australia</td>
<td>475</td>
<td>0</td>
<td>77</td>
<td></td>
</tr>
<tr>
<td>2016</td>
<td>Maffongelli</td>
<td>AIDS</td>
<td>Prospective cohort</td>
<td>Italy</td>
<td>116</td>
<td>0</td>
<td>100</td>
<td></td>
</tr>
<tr>
<td>2016</td>
<td>Nduka</td>
<td>Int J Cardiol</td>
<td>Cross-sectional</td>
<td>Nigeria</td>
<td>406</td>
<td>0</td>
<td>75</td>
<td></td>
</tr>
<tr>
<td>2016</td>
<td>Pirro</td>
<td>Sci Rep</td>
<td>Cross-sectional</td>
<td>Italy</td>
<td>170</td>
<td>0</td>
<td>100</td>
<td></td>
</tr>
<tr>
<td>2016</td>
<td>van Zoest</td>
<td>Clin Infect Dis</td>
<td>Prospective cohort</td>
<td>The Netherlands</td>
<td>527</td>
<td>517</td>
<td>95</td>
<td></td>
</tr>
<tr>
<td>2017</td>
<td>Ascher</td>
<td>Hypertension</td>
<td>Prospective cohort</td>
<td>The United States</td>
<td>823</td>
<td>267</td>
<td>59</td>
<td></td>
</tr>
<tr>
<td>2017</td>
<td>Ding</td>
<td>AIDS Res Hum Retroviruses</td>
<td>Cross-sectional</td>
<td>China</td>
<td>345</td>
<td>345</td>
<td>87</td>
<td></td>
</tr>
<tr>
<td>2017</td>
<td>Rodriguez-Arboli</td>
<td>PLoS One</td>
<td>Prospective cohort</td>
<td>Tanzania</td>
<td>834</td>
<td>0</td>
<td>76</td>
<td></td>
</tr>
</tbody>
</table>

ART indicates antiretroviral therapy.
### Table 2. Summary of Results for Published Human Studies of Novel Mechanisms for Hypertension in HIV-Infected Adults

<table>
<thead>
<tr>
<th>First Author, Year, Journal</th>
<th>Results</th>
<th>Novel Mechanism Supported</th>
</tr>
</thead>
<tbody>
<tr>
<td>Thébaut, 2005; Antivir Ther</td>
<td>Factors associated with new-onset hypertension included male sex, higher BMI, older age, higher BP at baseline, and clinical lipodystrophy</td>
<td>Lipodystrophy</td>
</tr>
<tr>
<td>Crane, 2006; AIDS</td>
<td>Lopinavir/ritonavir was significantly associated with an increased incidence of new-onset hypertension (OR, 2.5; ( P=0.03 ))</td>
<td>Antiretroviral therapy (protease inhibitors)</td>
</tr>
<tr>
<td>Palacios, 2006; HIV Med</td>
<td>Higher SBP at follow-up was significantly associated with older age, higher baseline SBP, high total cholesterol, and lower baseline CD4 T-cell count</td>
<td>Dyslipidemia, immune suppression/reconstitution</td>
</tr>
<tr>
<td>Baekken, 2008; Nephrol Dial Transplant</td>
<td>Microalbuminuria was more common in HIV-infected adults (compared with HIV-negative adults) and was associated with higher BP</td>
<td>Renal disease (microalbuminuria)</td>
</tr>
<tr>
<td>Baekken, 2008; J Hypertens</td>
<td>Statistically significant predictors of new-onset hypertension: older age, higher BMI, higher total cholesterol, longer duration of ART, and microalbuminuria</td>
<td>Dyslipidemia, antiretroviral therapy, renal disease</td>
</tr>
<tr>
<td>Crane, 2009; HIV Med</td>
<td>Lipohypertrophy (OR, 4.3; ( P=0.006 )) and lipoatrophy (OR, 5.5; ( P=0.01 )) were both associated with hypertension</td>
<td>Lipodystrophy</td>
</tr>
<tr>
<td>Freitas, 2012; J Clin Hypertens (Greenwich)</td>
<td>Compared with normotensive HIV-infected adults, HIV-infected adults with hypertension had higher total fat, central, and central/peripheral fat mass ratios</td>
<td>Lipodystrophy</td>
</tr>
<tr>
<td>Glyn, 2013; J Hum Hypertens</td>
<td>Low eGFR was associated with higher BP and higher L-arginine levels in HIV-infected African men but not uninfected men</td>
<td>Renal disease (L-arginine)</td>
</tr>
<tr>
<td>Hadigan, 2013; Am J Nephrol</td>
<td>Microalbuminuria was associated with new-onset hypertension, low CD4 T-cell counts (&lt;200 cells per µL), and ritonavir use</td>
<td>Renal disease, immune suppression, ART</td>
</tr>
<tr>
<td>Manner, 2013; HIV Med</td>
<td>LPS and sCD14, both markers of microbial translocation, independently predicted new-onset hypertension in ART-naive, HIV-infected adults</td>
<td>Microbial translocation, chronic inflammation</td>
</tr>
<tr>
<td>Manner, 2013; J Clin Hypertens (Greenwich)</td>
<td>Nadir CD4 cell count &lt;50 cells per µL (aOR, 2.48; 95% CI, 1.27–4.83) and ART duration (aOR, 1.13; 95% CI, 1.03–1.24) independently predicted new-onset hypertension</td>
<td>Immune suppression, antiretroviral therapy</td>
</tr>
<tr>
<td>Morimoto, 2014; Nutrition</td>
<td>HIV-infected adults with metabolic syndrome had higher SBP and DBP measurements and lower plasma adiponectin levels than those without</td>
<td>Dyslipidemia, adipokines</td>
</tr>
<tr>
<td>Peck, 2014; BMC Med</td>
<td>Age, alcohol use, BMI, microalbuminuria, low eGFR, and higher current CD4 T-cell count were independently associated with hypertension.</td>
<td>Renal disease, immune reconstitution, ART</td>
</tr>
<tr>
<td>Tenorio, 2014; J Infect Dis</td>
<td>Among HIV-infected adults on ART, elevated IL-6 was strongly associated with hypertension at baseline (OR, 1.6; ( P&lt;0.001 )) and at 1 y (OR, 1.8; ( P&lt;0.001 ))</td>
<td>Chronic inflammation</td>
</tr>
<tr>
<td>Rokx, 2015; AIDS Res Hum Retroviruses</td>
<td>Switching from a nevirapine- to a rilpivirine-based regimen led to a 6-mm Hg reduction in SBP at 24 and 48 wk (95% CI, (-1.7 \text{ to } -10.3; P=0.007))</td>
<td>Antiretroviral therapy (NNRTI)</td>
</tr>
<tr>
<td>Wensink, 2015; PLoS One</td>
<td>In HIV-infected adults on ART, albuminuria was significantly associated with hypertension, diminished eGFR, and increased HIV viral load</td>
<td>Renal disease (microalbuminuria)</td>
</tr>
<tr>
<td>Castley, 2016; PLoS One</td>
<td>CXCL10, sCD163, and sCD14 remained elevated, despite ART use and were associated with total cholesterol and LDL-c levels but not hypertension</td>
<td>Chronic inflammation, dyslipidemia</td>
</tr>
<tr>
<td>Maffongelli, 2016; AIDS</td>
<td>X4-tropic HIV (but not R5-tropic virus) independently predicted new-onset hypertension (HR, 2.29; 95% CI, 1.39–3.76; ( P&lt;0.001 ))</td>
<td>HIV tropism</td>
</tr>
<tr>
<td>Nduka, 2016; Int J Cardiol</td>
<td>A propensity score matching model estimated the average treatment effect of ART on SBP and DBP to be 7.85 and 7.45 mm Hg, respectively (( P&lt;0.001 ))</td>
<td>Antiretroviral therapy</td>
</tr>
</tbody>
</table>

(continued)
The mechanism by which lipopolysaccharide induces endothelial dysfunction may be mediated, in part, by long-term ART use. One cross-sectional study found that among the 46 participants on long-term ART (mean duration, 2 years), lipopolysaccharide concentrations were significantly associated with brachial artery flow-mediated dilation—a marker of endothelial function (r = -0.33; P = 0.02). Elevated lipopolysaccharide was not associated with endothelial function in ART-naïve adults or those on ART for only 6 months.44

**Chronic Inflammation**

**Inflammatory Biomarkers**

Several studies have demonstrated that inflammatory markers of HIV-related chronic immune activation are associated with hypertension. Elevated IL (interleukin)-6 levels have been shown to precede and predict hypertension in HIV-infected adults (OR, 1.8; 95% CI, 1.4–2.5; P < 0.001).34 Elevated IL-6 levels have similarly been associated with hypertension,51,52 as well as cardiovascular mortality among HIV-uninfected adults.53 In a genome-wide association analysis of 3000 older HIV-uninfected adults,65 the investigators found that compared with HIV-infected adults, such as RBP-4 (retinol-binding protein 4), a direct association with hypertension has not yet been tested.56 Additionally, some investigators have described the influence of other coinfections, such as cytomegalovirus infection, in the disruption of mucosal barriers and activation of downstream inflammatory pathways that later influence cardiovascular events.34 Although cytomegalovirus has been associated with a greater risk of non–AIDS-defining events, including cardiovascular disease, among HIV-infected adults (hazard ratio, 1.53; 95% CI, 1.05–2.16; P = 0.016),37 its association with hypertension has not been specifically examined. Numerous data have shown that premature cardiovascular disease among HIV-infected adults is at least, in part, because of immune activation and chronic inflammation, despite viral suppression,54,55 but the specific role of immune activation and chronic inflammation in hypertension was not examined in most of these studies.

**ART-Mediated Inflammation**

Protease inhibitors (PIs) have been shown to trigger inflammatory pathways. An in vitro study done on PI-treated human adipocytes demonstrated PI-mediated generation of ROS both through mitochondrial effects and macrophage accumulation, leading to alterations of adipocyte-native cytokines.60 The relationship between vascular ROS and hypertension was established in murine models of genetically modified mice, in which ROS overproduction was shown to also be associated with vascular collagen deposition, arterial stiffening, and kidney injury.61

### Table 2. Continued

<table>
<thead>
<tr>
<th>First Author, Year, Journal</th>
<th>Results</th>
<th>Novel Mechanism Supported</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pirro,34 2016; Sci Rep</td>
<td>Endothelial dysfunction was independently associated with hypertension, HIV RNA levels, and microalbuminuria in HIV-infected adults</td>
<td>Renal disease, chronic vascular inflammation</td>
</tr>
<tr>
<td>van Zoest,15 2016; Clin Infect Dis</td>
<td>Prior stavudine use independently predicted new-onset hypertension among HIV-infected adults. The effect was attenuated after adjustment for abdominal obesity</td>
<td>Antiretroviral therapy (NRTI), lipodystrophy</td>
</tr>
<tr>
<td>Acher,46 2017; Hypertension</td>
<td>Higher urine albumin-to-creatinine levels and lower eGFR independently predicted new-onset hypertension in HIV-infected but not HIV-uninfected women</td>
<td>Renal disease (microalbuminuria)</td>
</tr>
<tr>
<td>Ding,41 2017; AIDS Res Hum Retroviruses</td>
<td>Lower nadir CD4 T-cell count (&lt;50 cells per µL) was independently associated with hypertension but only in HIV-infected adults who were underweight or obese</td>
<td>Immune suppression/reconstitution</td>
</tr>
<tr>
<td>Rodríguez-Arboli,47 2017; PLoS One</td>
<td>Age, BMI, and eGFR, but not ART exposure or CD4 count, were found to be independent predictors of new-onset hypertension among HIV-infected adults</td>
<td>Renal disease</td>
</tr>
</tbody>
</table>

aOR indicates adjusted odds ratio; ART, antiretroviral therapy; BMI, body mass index; BP, blood pressure; CD, cluster of differentiation; CI, confidence interval; CXCL 10, C-X-C motif chemokine ligand 10; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; HR, hazard ratio; IL, interleukin; LDL-c, low-density lipoprotein cholesterol; LPS, lipopolysaccharide; NNRTI, non-nucleoside reverse transcriptase inhibitor; NRTI, nucleoside reverse transcriptase inhibitor; OR, odds ratio; SBP, systolic blood pressure; and sCD, soluble cluster of differentiation.
Role of Macrophages
The role of macrophages in hypertension among the general population has been previously demonstrated in murine models of hypertension. For instance, when compared with wild-type mice, genetically modified mice incapable of producing macrophage-derived 12/15 lipoxygenase did not develop elevated blood pressure when exposed to various hypertensive precipitants, including deoxycorticosterone acetate/high-salt environment, and Nω-nitro-L-arginine-methyl ester—an inhibitor of NO synthase. Furthermore, knockout mice demonstrated elevated blood pressures in response to these stimuli after adoptive transfer of wild-type macrophages, whereas wild-type mice became resistant to the hypertensive effects of Nω-nitro-L-arginine-methyl ester after clodronate-induced macrophage depletion. Such findings suggest an association between innate immunity and hypertension and warrant further exploration in the context of HIV infection.

Role of Myeloid Cells
Myelomonocytic and other cells of myeloid origin have been shown to be directly involved in the pathogenesis of arterial hypertension and deserve greater attention as a possible mechanism for hypertension in the context of HIV infection. For instance, in 3 mechanistically distinct murine models of hypertension, male mice with hypertension were observed to have higher levels of myeloid-derived suppressor cells (MDSCs), which in turn attenuated the pathological splenic hyperactivity of T cells and proinflammatory cytokines interferon-γ, tumor necrosis factor-α, and IL-17. When wild-type MDSCs were transferred into these hypertensive mice, the blood pressure decreased. HIV infection has been shown to effect MDSCs in multiple ways. Advanced HIV disease is associated with both increased MDSC activity and MDSC deficiency. In addition, persistently elevated levels of MDSC activity have been observed even in aviremic HIV-infected individuals on ART. To the best of our knowledge, no published research has yet explored the relationship between MDSCs and hypertension in the context of HIV infection.

Gut Microbiome
A growing body of literature has implicated abnormalities in the gut microbiome as an important mechanism for hypertension, and this deserves greater attention as a possible mechanism in the context of HIV infection. Animal models of hypertension have shown that when compared with conventionally raised mice, germ-free mice exposed to angiotensin II infusion had a less robust systemic inflammatory response, lower systolic blood pressure, and less end-organ damage. Two human studies have confirmed that gut dysbiosis is more common in adults with hypertension when compared with normotensive controls. There is likely a complex relationship between hypertension, the gut microbiome, and immune activation. In 1 study, for example, the administration of a high-salt diet to healthy volunteers was associated with increased blood pressure, reduction of intestinal Lactobacillus spp., and increase in CD4+ TH17 cell activity. Furthermore, Lactobacillus murinus supplementation in salt-sensitive, hypertensive mice exposed to a high-salt diet was associated with attenuated TH17 activity and decreased blood pressures. HIV itself has multiple effects on the gut microbiome, and there are several ongoing trials examining the effects of probiotics on the gut microbiome and systemic inflammatory state of HIV-infected adults. We hope that these studies have included hypertension as a rigorously measured outcome.

Immune Reconstitution
CD4 T cells have been shown to be critical in the pathophysiology of hypertension in the general population. Knockout mice incapable of producing T cells do not develop hypertension in response to angiotensin II infusion. In HIV-infected adults, CD4 T-cell counts drop dramatically and then rise rapidly after the initiation of ART. Lower nadir CD4 T-cell counts have been associated with higher incidence of hypertension after ART initiation in several studies. Replicated by multiple investigators, these findings suggest that hypertension in HIV-infected adults on ART may be a phenomenon of immune suppression and reconstitution. This theory was supported by a subanalysis.
of 332 HIV-infected adults enrolled in a large randomized clinical trial of immediate versus deferred ART initiation among immune reconstitute HIV-infected individuals. Investigators found that in individuals with baseline CD4 counts >500 cells per mm³, ART exposure did not increase blood pressures or arterial stiffness. Another cross-sectional study done on 300 ART-experienced and 45 ART-naive HIV-infected adults in China found that a nadir CD4 T-cell count <50 cells per mm³ was associated with increased prevalence of hypertension in overweight participants (body mass index, <18.5 kg/m²) with an adjusted OR of 18.91 (P = 0.043) but not in normal or overweight participants. The influence of nadir CD4 count on hypertension can be explained, in part, by the concept of early aging or immunosenescence. HIV-infected young adults have immunologic profiles that are similar to older HIV-uninfected adults, and this senescent immunologic profile persists in HIV-infected adults even after the initiation of ART and viral suppression. In HIV-uninfected populations, shortened telomere length is a genetically mediated marker of immune senescence. The HIV virus seems to induce premature telomeric shortening through mitochondrial dysfunction. Although immune senescence, through telomere shortening, has been proposed to explain the increased cardiovascular risk in HIV-infected adults, its specific relationship to hypertension has not yet been evaluated.

The relationship between immunosuppression and hypertension may also be related to HIV tropism. Investigators demonstrated that ART-experienced patients infected with an R5-tropic virus were less likely to experience hypertension than those infected with an X4-tropic virus (absolute risk reduction, 47.6%). This difference may be because of the more aggressive behavior of the X4-tropic viral strain, which has been associated with lower nadir CD4 counts.

**Lipodystrophy, Dyslipidemia, and Adipocytokines**

**Lipodystrophy**

Both ART and HIV itself can cause lipodystrophy—an umbrella term encompassing lipoatrophy and lipohypertrophy. Lipodystrophy may cause hypertension through simultaneous accumulation of central adiposity and atrophy of peripheral adiposity. In a cross-sectional study of HIV-infected adults on ART, this association remained statistically significant even when accounting for body mass index and other confounders. Furthermore, a cross-sectional study of HIV-infected adults with variable ART exposure found that both lipoatrophy and lipohypertrophy independently predicted hypertension. After adjusting for body mass index, patients with moderate lipatrophy had a 5-fold greater risk of hypertension as compared with those without lipodystrophy (adjusted OR, 5.5; P = 0.01). HIV- and ART-related lipodystrophy and lipohypertrophy have also been associated with the RAAS dysregulation that causes hypertension. For instance, a study of angiotensin II and adrenocorticotropic hormone infusion into HIV-infected adults found that HIV-related visceral lipohypertrophy was independently associated with RAAS activation even in low-sodium conditions, with elevated median plasma renin activity among those with increased visceral adipose tissue (3.50 ng/mL per hour) compared with those without increased adipose tissue (1.45 ng/mL per hour; P = 0.002).

The use of PIs specifically has been associated with lipodystrophy and perturbations in lipid homeostasis that may be linked to hypertension and cardiovascular disease. An in vitro study of mouse macrophages found that PIs disturb protein folding, causing imbalances in intracellular cholesterol and calcium stores, promoting gene expression of certain proteins involved in lipid metabolism of macrophages, and triggering pathways that ultimately result in cell apoptosis. These mechanisms may be implicated in the pathophysiology of cardiovascular disease. The effects on lipid metabolism were also suggested by a subanalysis of a prospective cohort study on HIV-infected individuals on PI-based regimens, which found an association between PI-related lipodystrophy and diminished levels of PPAR-γ (peroxisome proliferator activator receptor-γ), which regulate genes involved in lipid homeostasis and inflammation. These findings were supported by an in vitro study on human and murine adipocytes, which found that PPAR-γ agonist exposure attenuated PI-induced RAAS activation but that PPAR antagonists increased RAAS activation. The relationship between PPAR-γ and RAAS has been extensively explored in the general population using murine models of dominant negative mutations of PPAR-γ, which are associated with hypertension in humans. For instance, when exposed to angiotensin II infusions, transgenic, but not wild-type, mice demonstrated attenuated vasodilatory responses to acetylcholine exposure, although this effect was reversed in the presence of a superoxide scavenger, suggesting that the protective mechanisms of PPAR-γ may be related to RAAS-mediated oxidative stress. Similar in vitro studies examining the downstream vascular effects of PIs on PPAR-γ and angiotensin II are warranted to explore their potential role as possible mediators of hypertension in the setting of HIV infection.

**Role of Adiponectin**

The pathophysiologic mechanisms by which HIV-related dyslipidemias induce hypertension are likely related to the adipocytokines adiponectin and leptin. Adiponectin—an adipose tissue-derived cytokine and adipokine—acts as a vasodilator by stimulating endothelial NO, and thus its deficiency has been shown to be critical in the pathogenesis of obesity-related hypertension in the general population. In the context of HIV infection, decreased plasma levels of adiponectin have similarly been associated with metabolic syndrome. For instance, in a cross-sectional study of 54 HIV-infected children and adolescents, adiponectin levels were significantly lower among those with metabolic syndrome (P = 0.004). Similarly, in a case–control study of 285 HIV-infected individuals (226 on ART; 59 ART naive) stratified by metabolic syndrome, lower adiponectin levels (P = 0.0001) and higher concentrations of ROS (P < 0.0001) were observed in the plasma of patients with metabolic syndrome, irrespective of ART status. Notably, no studies have directly analyzed the relationship between adiponectin and hypertension in HIV infection.

**Role of Leptin**

Leptin—an adipokine generated by inflammatory cascades that are also activated in HIV infection—acts primarily on the aorta and hypothalamus. HIV-infected individuals on ART have been shown to have elevated leptin concentrations...
irrespective of body mass index.91 In the aorta and hypothalamus, leptin receptors trigger the activation of both the RAAS and the sympathetic nervous system.87,90 In a family-based association analysis of the leptin gene among 695 individuals from 82 families, several single-nucleotide polymorphisms that were significantly associated with higher plasma leptin concentrations were also associated with hypertension in women ($\beta$=0.48; 95% CI, 0.25–0.72; $P<0.001$) but not in men.92 Several mechanisms may explain the association between elevated leptin and hypertension. First, murine models of hypertension have shown that leptin centrally activates the RAAS system.87,90 In addition, elevated leptin activates the sympathetic nervous system.90,92 Leptin also activates the RAAS and the central nervous system through direct effects on the medulla oblongata and by inducing production of acute-phase reactants from the liver.90,94

**Neuroendocrine Response**

HIV-mediated activation of the sympathetic nervous system may also be important in the pathophysiology of hypertension in HIV-infected adults. Already mentioned are the effects of adipokines on increased sympathetic tone.87,90,93,94 Additionally, both lipopolysaccharide and centrally acting macrophage-derived inflammatory cytokines appear to generate a similar neuroendocrine response.23,90,95 Also, HIV-infected adults with lipodystrophy have localized elevations of noradrenaline concentrations within adipose tissue and skeletal muscle.96 ART may also directly affect monoamine oxidase activity through mitochondrial derangements or possibly influencing postsynaptic norepinephrine reuptake.96

This neuroendocrine hyperactivity may be partially explained by psychosocial influences that have been shown to play a role in hypertension, with investigators implicating stressors, such as HIV-related stigma and mood disorders in autonomic dysfunction and disturbances of circadian rhythm.97–99 The influence of circadian rhythm derangement is further supported by the observation that even among HIV-infected individuals who did not meet diagnostic criteria for hypertension, there was a greater likelihood of elevated nocturnal pressures and a lesser incidence of dipping systolic blood pressure, both of which may be harbingers of impending hypertension.97,100,101

**HIV-Related Renal Disease**

**Microalbuminuria**

Microalbuminuria—a marker of renal injury—has been shown in multiple studies to be independently associated with hypertension in HIV-infected participants.5,29,36,39,40 HIV-infected adults have been shown to have higher rates of albuminuria than uninfected adults,5,29,102 with a prevalence estimated to be ≤4x greater than that of the general population.91 These higher rates of albuminuria in HIV-infected adults are partly attributable to direct HIV viral effect and partly because of chronic inflammation.5,30,40 A recent multicenter, prospective cohort study of 823 HIV-infected and 267 HIV-uninfected women followed during a median of 10 years found microalbuminuria to be an independent predictor of incident hypertension (relative risk, 1.13 per urine albumin-to-creatinine ratio doubling; 95% CI, 1.07–1.29).40 These studies suggest that hypertension ultimately occurs through renally mediated mechanisms of sodium imbalance and RAAS activation.29,39,40

**Role of L-Arginine**

L-arginine—a NO precursor—may also be an important mediator in the relationship between renal disease and hypertension in HIV-infected adults.32 In the general population, L-arginine deficiency has previously been shown to cause vasocostriction and hypertension.103 One cross-sectional analysis of HIV-infected and HIV-uninfected South African men demonstrated that low estimated glomerular filtration rate was common in HIV-infected men and was associated with higher L-arginine levels ($P<0.002$).32

**Other**

**HIV-Related RAAS Activation**

Abnormal RAAS activation may play a critical role in the pathophysiology of hypertension in HIV infection. HIV-infected people demonstrated increased RAAS activity as a result of several upstream pathways.28,31 HIV-infected adults have high plasma renin activity, even in low-sodium environments.89 This may be explained by the structure of HIV-1 protease, which is similar to renin.104,105 The virus has been shown to promote the production of renin by CD4 T cells, which are a source of endogenous RAAS activation.105 Reciprocally, renin interacts directly with the HIV virus to promote viral replication.104,105 In 1 in vitro study, renin was shown to be critical to HIV replication within T cells, presumably by adopting the role of HIV protease and interacting with its receptor (P)RR.105 Investigators found that HIV-infected T cells incubated in a renin-rich medium, compared with those in a renin-free buffer, exhibited a 3-fold increase in the concentration of p24 (an essential viral protein).105 Furthermore, the addition of a direct renin inhibitor was shown to decrease the production of both HIV viral proteins.105

**Arterial Stiffness**

PIs may cause arterial stiffness—an established independent risk factor for hypertension. Arterial stiffness has been shown to induce elevated central pulse pressure, sympathetic activation, and left ventricular hypertrophy.37 A large, prospective cohort study of ART-treated HIV-infected patients without hypertension found that patients on the PIs lopinavir/ritonavir were twice as likely as those on other ART drugs to develop hypertension.37 Schillaci et al93 showed that compared with HIV-uninfected controls, HIV-infected patients on PIs had a greater degree of aortic stiffness, as measured by higher aortic pulse wave velocity (7.6±1.1 versus 6.8±1.2 m/s$^2$; $P=0.015$) and aortic augmentation (6.8±5 versus 4.6±4 mmHg; $P=0.037$). The end-organ effects of arterial stiffness and endothelial dysfunction are likely the direct consequence of vascular inflammation.10

**Protease Inhibitors**

PIs have been implicated in the pathophysiology of hypertension in HIV-infected adults through numerous mechanisms including RAAS activation, endothelial dysfunction, arterial stiffness, lipodystrophy, and dyslipidemia.24,27,30,60,82,83 The effects on endothelial dysfunction, arterial stiffness, lipodystrophy, and dyslipidemia have already been each discussed in dedicated subsections above.
The use of PIs is associated with RAAS activation. Acting on adipocytes directly, the PI combinations ritonavir/lopinavir and ritonavir/atazanavir were shown to activate adipokine-mediated inflammatory pathways that led to activation of adipose RAAS. An in vitro study of human and murine adipocytes demonstrated 54-fold increase of angiotensin receptor protein expression after only 5 days of exposure to lopinavir/ritonavir or atazanavir/ritonavir. This effect was prevented by the use of RAAS antagonists.

**Nucleoside and Non-Nucleoside Reverse Transcriptase Inhibitors**

Certain nucleoside reverse transcriptase inhibitors may also play some role in the pathophysiology of hypertension in HIV-infected adults, although data are conflicting. One prospective cohort study of 444 HIV-infected adults without hypertension at baseline found that combination therapy with lamivudine and tenofovir as compared with lamivudine and zidovudine was associated with an increased risk of hypertension (OR, 2.3; 95% CI, 1.0–5.2; \( P = 0.046 \)).27 Similarly, a subanalysis of a prospective cohort study of 527 HIV-infected and 517 HIV-uninfected adults found that prior stavudine exposure was independently associated with hypertension (OR, 1.54; 95% CI, 1.04–2.30). Other studies, including our own, have shown no relationship between nucleoside reverse transcriptase inhibitor use and hypertension.5

There have been fewer studies exploring the association between non-nucleoside reverse transcriptase inhibitors and hypertension. However, a prospective open-label clinical trial that evaluated the cardiometabolic outcomes after HIV-infected participants were switched from an older generation (nevirapine) to a newer generation non-nucleoside reverse transcriptase inhibitors (rilpivirine) demonstrated a mean systolic blood pressure decrease of 6.0 mm Hg (95% CI, −1.7 to −10.3; \( P = 0.007 \)) after 24 weeks of therapy.35

**How Much of Hypertension in HIV-Infected Adults Is Simply Attributable to ART?**

Direct ART effect may explain some but not all of the increased risk of hypertension in HIV-infected adults. HIV-infected participants on ART have higher rates of hypertension than ART-naive HIV-infected people.5,10,15,24,26–28,30,38,42,106 Although no published studies have quantified the hypertensive risk directly attributed to ART use, many studies done on ART-experienced HIV-infected participants have identified other independent risk factors for hypertension, including nadir CD4 count <50 cells per µL (adjusted OR, 2.48; 95% CI, 1.27–4.83),22 lipodystrophy (OR, 4.80; 95% CI, 2.43–9.85; \( P < 0.0001 \)),4 lipatrophy (OR, 4.3; 95% CI, 1.5–12.4; \( P = 0.006 \)),21 renal dysfunction,3,5,10,40,42 and HIV tropism.25 In addition, the higher prevalence of hypertension in ART-experienced adults may be because of the immune reconstitution caused by these drugs rather than direct drug effect on blood pressure.7,41

Findings from observational studies describing HIV-infected adults on different ART regimens should be interpreted with caution for several reasons. First, there is the possibility of selection bias because there may be underlying clinical factors justifying the use of a particular antiretroviral regimen that may consequently influence the development of hypertension. Furthermore, the studies evaluating ART and hypertension also suffer from potential confounding by heterogeneity between and within ART classes and relatively sparse information on mechanisms by which ART may cause hypertension. Finally, the comparison of people on ART versus not on ART may be problematic because several studies have postulated that poor HIV control is actually associated with lower blood pressure because of greater vascular permeability and a perisceptic state.5,18,107 Randomized trials are warranted to account for potential confounders and better understand the independent cardiovascular effects of ART.

**Future Directions and Treatment Implications**

In this review, we have summarized what is known about the mechanisms for hypertension in HIV-infected adults. It is important to note that most of the published research that we reviewed described more generally the pathophysiology of cardiovascular disease in the context of HIV and did not look more specifically at the pathophysiology of hypertension. More basic science and clinical research is needed to investigate whether these pathways that have been proven to lead to cardiovascular disease in HIV-infected populations are the same pathways that lead to hypertension or whether other pathways are important for hypertension.

Larger, multinational prospective studies are needed to determine the mechanistic factors that precede and predict hypertension in HIV-infected adults. Most human data on hypertension in HIV-infected adults come from cross-sectional studies, and debates in the literature on potential mechanisms for hypertension in HIV-infected adults have resulted from conflict between cross-sectional studies.41,108 Surprisingly few of the large cohorts of HIV-infected adults have included rigorous measurement of blood pressure.

The best method for screening for hypertension and the optimal threshold for starting antihypertensive medications should also be determined. None of the current guidelines provide specific recommendations related to HIV-infected adults.109,110 There may be a role for universal ambulatory blood pressure monitoring, which has been validated in the general population as an independent predictor of cardiovascular disease outcomes105 because studies have demonstrated a high prevalence of abnormal diurnal blood pressure patterns and masked hypertension among HIV-infected adults undergoing ambulatory blood pressure monitoring screening.97,100

Interventional studies of novel approaches to prevent or treat HIV-infected adults targeting the pathways described above are needed. Small studies of RAAS antagonists have yielded promising results.111,112 Telmisartan, which acts as both an angiotensin receptor blocker and a PPAR-γ agonist, is particularly effective. One longitudinal prospective study of 13 hypertensive, HIV-infected males on ART found that telmisartan use reduced systolic (−9.2 ± 3.4 mm Hg; \( P = 0.006 \)) and diastolic blood pressure (−11.9 ± 2.9 mm Hg; \( P = 0.001 \)) after 3 years.112 In another prospective study of 18 virologically suppressed HIV-infected males, telmisartan use greatly reduced systolic (20.00 mm Hg; \( P = 0.001 \)) and diastolic (13.34 mm Hg; \( P = 0.001 \)) blood pressures after 6 months.111

To date, though, there have not been any large-scale trials evaluating the role of RAAS antagonists in the prevention and treatment of hypertension in HIV. Given the pivotal role
that renin plays both in the initiation of the RAAS cascade and mediation of viral replication, RAAS antagonists could result in significant clinical benefit in HIV-infected adults. Additionally, interventional studies exploring therapies that target chronic inflammation, lipopolysaccharide, and leptin are likely warranted.

**Conclusions**

In summary, hypertension is common in HIV-infected adults and is likely because of a combination of traditional risk factors, HIV-specific factors, and ART. We have described the current evidence for possible mechanisms of hypertension in HIV-infected adults related to HIV-specific factors and ART. Novel pathophysiologic mechanisms for hypertension in HIV-infected adults may include microbial translocation, chronic inflammation, immune suppression and reconstitution, viral tropism, lipodystrophy, adipokines, and HIV-related renal disease. Large, multinational cohort studies are needed to solidify our knowledge. In addition, interventional studies are needed to discover new interventions for preventing and treating hypertension and hypertension-related cardiovascular disease in HIV-infected adults.

**Acknowledgments**

We are grateful to Kevin Pain, Research Specialist, Weill Cornell Medical Library, for his assistance in developing and performing the literature search on which our review is based.

**Sources of Funding**

S.A. Fahme is supported by the postdoctoral global health research fellow at Weill Cornell Medical College. R. Peck is supported by a career development grant from the Fogarty International Institute of the National Institutes of Health (K01 TW01281).

**Disclosures**

None.

**References**


27. Crane HM, Van Rompaey SE, Kitahata MM. Antiretroviral medica-


35. Rokx C, Verbom A, Rijnders BJ. Short communication: lipids and car-


37. Bannerman DD, Goldblum SE. Mechanisms of bacterial lipopolysaccha-


39. Zhang ZH, Yu Y, Wei SG, Felder RB. Centrally administered lipopolysaccha-


44. Reiner AP, Lange EM, Jenny NS, Chaves PH, Ellis J, Li J, Walston J, Lange LA, Cushman M, Tracy RP. Soluble CD14: genomewide asso-


46. Jeong SJ, Chin BS, Chae YT, Jin SJ, Ku NS, Baek JH, Han SH, Kim CO, Choi JY, Song YG, Lee HC, Kim JM. Serum retinol-binding pro-


48. Longnecker CT, Sullivan CJ, Baker JV. Immune activation and car-


